BioCentury
ARTICLE | Financial News

Keryx, NewLink propose follow-ons

January 30, 2013 2:27 AM UTC

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and NewLink Genetics Corp. (NASDAQ:NLNK) proposed follow-ons late Tuesday. Keryx said it plans to raise $55 million in a follow-on underwritten by JPMorgan. On Monday, the company jumped 77% after reporting that Zerenex ferric citrate met the primary endpoint in a Phase III trial to treat hyperphosphatemia in patients with end-stage renal disease (ESRD). Keryx plans to submit an NDA to FDA and an MAA to EMA for Zerenex in 2Q13. On Tuesday, Keryx was up $2.30 (38%) to $8.36 (see BioCentury Extra, Jan. 28). ...